HVEM Kit ELISA

N° du produit ABIN2952172

Détail du produit HVEM Kit ELISA

Antigène: HVEM (TNFRSF14) (Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Competition ELISA

Gamme de detection: 31.2 pg/mL - 2000 pg/mL

Seuil minimal de détection: 31.2 pg/mL

Application: ELISA

Fonction: Human Tumor necrosis factor receptor superfamily member 14 ELISA Kit is an ELISA kit against Human Tumor necrosis factor receptor superfamily member 14 (TNFRSF14).

Type d'échantillon: Plasma, Serum

Analytical Method: Quantitative

Sensibilité: < 15 pg/mL

Information d'application

Indications d'application:

Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5 % within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Stock: 4 °C/-20 °C

Stockage commentaire: Upon receipt, store the kit according to the storage instruction in the kit's manual.

Date de péremption: 6 months

Détail du antigène

Antigène: HVEM (TNFRSF14) (Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14))

Autre désignation: Tumor Necrosis Factor Receptor Superfamily Member 14 (TNFRSF14 Produits)

Synonymes: ATAR Kit ELISA, CD270 Kit ELISA, HVEA Kit ELISA, HVEM Kit ELISA, LIGHTR Kit ELISA, TR2 Kit ELISA, Atar Kit ELISA, HveA Kit ELISA, Hvem Kit ELISA, Tnfrs14 Kit ELISA, TNF receptor superfamily member 14 Kit ELISA, tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) Kit ELISA, Tnfrsf14 Kit ELISA, TNFRSF14 Kit ELISA

Classe de substances: Viral Protein

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints